AccuBioTech's Accu-Tell® RSV Antigen Test delivers results in 10 min (98.5% sensitivity), enabling early intervention for infants. Supports WHO's goal to reduce RSV deaths globally. Deployed in 50+ countries.
In response to the World Health Organization (WHO) publication, "WHO outlines recommendations to protect infants against RSV – respiratory syncytial virus", AccuBioTech Co., Ltd., an innovative biotechnology company specializing in rapid infectious disease testing, leverages its core product, the6-in-1 Health Monitor to provide an efficient solution for the early and accurate diagnosis of RSV infection in infants and young children worldwide. This supports the implementation of WHO's global public health goal of "reducing RSV-associated severe illness and death."
According to the latest WHO report, RSV is the leading cause of acute lower respiratory infections in children under 5 globally, causing approximately 100,000 deaths and 3.6 million hospitalizations annually. Nearly half of these deaths occur in infants under 6 months of age, with 97% concentrated in low- and middle-income countries with limited healthcare resources. Initial RSV infection symptoms resemble the common cold, but it can lead to serious complications like pneumonia and bronchiolitis, posing a significant threat particularly to high-risk groups such as preterm infants and those with congenital heart disease.
"Initial RSV infection symptoms resemble a cold but can rapidly progress to pneumonia or bronchiolitis," emphasized a WHO immunization expert. "Timely diagnosis is the first line of defense against severe disease progression."
As a core product in AccuBioTech's infectious disease testing portfolio, the Accu-Tell® RSV Antigen Cassette (Swab), based on advanced immunochromatographic technology, enables rapid qualitative detection of the RSV virus antigen. Its core advantages include:
Ultra-Fast Diagnosis: Provides results within 10 minutes, significantly reducing time-to-diagnosis compared to traditional laboratory tests, enabling clinicians to promptly initiate interventions like oxygen therapy and respiratory support.
Accurate & Reliable: Clinically validated (n=289 samples), the test boasts a sensitivity of 98.5% (concordance with RT-PCR) and specificity of 99.1%, effectively reducing missed diagnoses and misdiagnoses.
Convenient & User-Friendly: Compatible with various sample types including nasal swab, throat swab, and nasopharyngeal swab. Requires no specialized equipment and features a simple procedure, making it particularly suitable for primary healthcare settings and resource-limited regions.
"While vaccine and antibody prevention efforts advance, rapid diagnostics remain a core tool for surveillance," stated the Marketing Director of AccuBioTech. "Our product helps clinics quickly differentiate RSV from influenza, buying precious intervention time for high-risk infants."
The Accu-Tell® RSV Antigen Cassette (Swab) keeps costs affordable through mass production and a global distribution network. Currently deployed in over 50 countries, it has become a vital tool in combating epidemics for primary healthcare institutions.
Upholding its core values of "Responsibility, Teamwork, Innovation, and Continuous Improvement," AccuBioTech is working closely with global distributors to promote the adoption of its RSV testing products in more countries by providing customized training and responsive technical support.
Moving forward, AccuBioTech will continue to deepen its expertise in infectious disease diagnostics, aligning its technological innovations with prevention and control initiatives from international organizations like WHO, contributing Chinese wisdom and strength to safeguard the health of infants and young children globally and realize the vision of "health equity."